Mitochondrial peptides with different regulatory status

MOTS-c vs SS-31 (elamipretide): evidence, FDA status, and safety

Compare investigational MOTS-c with SS-31, also called elamipretide and sold by prescription as Forzinity for a narrow Barth syndrome indication, including evidence limits, label safety, July 2026 FDA PCAC context, and seller red flags.

Educational guideUpdated July 17, 2026

How to compare MOTS-c and SS-31 safely

Name the actual goal or diagnosis: Barth syndrome, unexplained weakness, fatigue, exercise tolerance, weight or glucose concerns, or broad longevity interest.

Confirm product identity. MOTS-c, research-labeled SS-31, and prescription Forzinity are not interchangeable names, products, or care pathways.

Check the regulatory boundary: MOTS-c has no FDA-approved indication; Forzinity has a narrow accelerated-approval label for eligible patients with Barth syndrome.

Match claims to evidence from the exact peptide, formulation, population, route, and outcome rather than transferring mitochondrial mechanisms between products.

Reject no-prescription checkout, research-use vials promoted for people, copied injection schedules, counterfeit Forzinity claims, and guaranteed energy, weight, performance, or longevity outcomes.

Direct answer

MOTS-c and SS-31 are different mitochondrial peptides and are not interchangeable. MOTS-c has mostly cell, animal, review, and human biomarker research; it has no FDA-approved indication. SS-31 is a research name for elamipretide. FDA-approved Forzinity contains elamipretide and is labeled under accelerated approval only to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. That label does not approve elamipretide for fatigue, weight loss, exercise performance, mitochondrial “optimization,” or anti-aging. Do not treat an online SS-31 vial as equivalent to the approved prescription product or use either peptide from a copied protocol.

Plain-English difference

MOTS-c is investigational; elamipretide has one narrow labeled use

MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied in metabolic-stress signaling. SS-31 is a research name used for elamipretide, a mitochondria-targeted peptide that binds cardiolipin. The current DailyMed label identifies the prescription product as Forzinity (elamipretide hydrochloride) injection. FDA approval of that specific product and indication does not turn every product sold as “SS-31” into an approved drug, and it does not validate broad mitochondrial, athletic, metabolic, fatigue, or longevity marketing.

MOTS-c has no FDA-approved label establishing a treatment indication, standardized dosing, contraindications, interactions, or long-term safety.
Forzinity is labeled to improve muscle strength in patients with genetically confirmed Barth syndrome who meet the label’s weight threshold—not for general wellness or anti-aging.
A research-use vial, compounded product, and FDA-approved finished drug are different categories even when a seller uses a familiar peptide name.

Evidence quality

Mitochondrial mechanisms do not prove the same patient outcome

A landmark MOTS-c paper reported metabolic effects in cells and mice. A small human exercise study measured circulating mitochondrial-derived peptides and found a trend toward higher MOTS-c after endurance exercise; it did not test administered MOTS-c as a treatment. Forzinity’s label describes a very small Barth syndrome program: the randomized study did not beat placebo on its primary six-minute-walk and fatigue endpoints, while knee-extensor strength improved during an open-label extension. FDA used that intermediate endpoint for accelerated approval, with continued approval potentially dependent on confirmatory evidence. These data cannot be compared as proof that either peptide improves energy, body composition, athletic performance, or lifespan in the general population.

Ask whether evidence comes from cells, animals, circulating biomarkers, an uncontrolled extension, a randomized trial, or the exact FDA-approved label.
Do not use cross-trial comparisons to call MOTS-c or elamipretide the “stronger” mitochondrial peptide.
Unexplained weakness, fatigue, exercise intolerance, or weight change may need evaluation for heart, lung, neurologic, metabolic, sleep, nutrition, medication, infection, or overtraining causes.

Label and safety boundaries

Forzinity safety information cannot be copied onto MOTS-c—or vice versa

The current Forzinity label reports injection-site reactions as the most common adverse reactions and warns about hypersensitivity, including serious allergic reactions. It lists serious hypersensitivity to elamipretide or product excipients as a contraindication, includes renal-impairment considerations, and says the product is not approved for neonates. MOTS-c has no approved label that defines comparable risks. The absence of a labeled warning for an investigational product is not evidence of safety, and an online seller’s SS-31 protocol is not a substitute for the Forzinity label, a diagnosis, or specialist care.

Do not self-switch between MOTS-c, SS-31, elamipretide, Forzinity, or another mitochondrial product based on name similarity or a seller’s conversion chart.
Review allergies, prior injection reactions, kidney function, pregnancy or breastfeeding, cancer treatment, diabetes medicines, cardiovascular history, surgery plans, and the full medicine and supplement list with the responsible clinician.
Seek urgent care for trouble breathing, swelling of the face or throat, fainting, or another severe allergic reaction rather than waiting for an online peptide seller.

FDA July watch

The July 2026 MOTS-c PCAC discussion is not drug approval

FDA scheduled MOTS-c free base and acetate for discussion at the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting as part of the section 503A bulks-list process. FDA meeting materials list obesity and osteoporosis as nominated uses for discussion. Before that future meeting occurs, no recommendation or outcome should be predicted. The meeting is not approval of MOTS-c, proof of effectiveness, a treatment recommendation, or validation of research-chemical sellers. It is also unrelated to the product-specific accelerated approval already described in the Forzinity label.

PCAC recommendations are advisory; FDA makes final determinations after considering committee input and completed reviews.
“FDA-approved MOTS-c,” “approved in July,” and “same as prescription SS-31” are misleading seller claims.
If a clinic discusses MOTS-c, ask for current legal and clinical status, an individualized prescription decision, licensed-pharmacy sourcing, evidence limits, monitoring, and stop criteria.

Choosing the right care path

Start with the diagnosis or symptom—not a mitochondrial stack

Barth syndrome is a rare genetic disorder that requires specialist diagnosis and management; a general telehealth or longevity comparison cannot establish eligibility for Forzinity. People without Barth syndrome who have fatigue, weakness, exercise intolerance, metabolic concerns, or healthy-aging goals need a cause-focused evaluation rather than an SS-31 or MOTS-c shopping decision. Starting several mitochondrial products together can obscure side effects, waste money, and delay appropriate care.

For suspected or confirmed Barth syndrome, use a genetics, cardiology, metabolic, or other specialist pathway and the current prescription label.
For broader symptoms, define objective baselines and address sleep, nutrition, medicines, heart or lung symptoms, anemia, thyroid or glucose concerns, and training load as appropriate.
Avoid no-prescription peptide checkout, products marked “research use only” for human use, hidden sourcing, copied schedules, and guaranteed mitochondrial-repair claims.

Patient safety checklist

Questions to ask before considering MOTS-c, SS-31, both, or neither

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

What exact symptom, diagnosis, or measurable goal am I trying to address, and does it need primary, specialist, urgent, or emergency evaluation?

✓

Is the proposed product MOTS-c, research-labeled SS-31, elamipretide, FDA-approved Forzinity, or another formulation—and can the label and source be verified?

✓

Does the claim match the exact peptide, route, population, clinical endpoint, and regulatory status rather than a shared “mitochondrial” theme?

✓

If Forzinity is being discussed, is there genetically confirmed Barth syndrome and specialist review under the current label?

✓

If MOTS-c is being discussed, is it described accurately as lacking an FDA-approved indication and as part of a still-evolving July 2026 compounding-policy review?

✓

Could kidney disease, allergies, prior injection reactions, pregnancy, cancer treatment, diabetes medicines, surgery, or another medicine or supplement change the risk?

✓

Who will monitor objective outcomes, adverse reactions, product quality, laboratory or specialist needs, and whether the plan should stop?

✓

Does the seller avoid research-use products for people, copied injection schedules, counterfeit approval claims, and guaranteed energy, weight, performance, or longevity outcomes?

FAQs

Short answers for patients

Are SS-31 and elamipretide the same thing?

SS-31 is a research name for elamipretide. The FDA-approved finished prescription product is Forzinity (elamipretide hydrochloride), with a narrow Barth syndrome indication. An online vial labeled SS-31 should not be assumed to be Forzinity or an FDA-approved product.

Is SS-31 FDA approved for anti-aging, energy, or exercise?

No. Forzinity is approved under the accelerated-approval pathway to improve muscle strength in patients with Barth syndrome who meet the label’s criteria. That does not approve SS-31 or elamipretide for anti-aging, fatigue, exercise performance, weight loss, or general mitochondrial optimization.

Is MOTS-c FDA approved?

No. MOTS-c has no FDA-approved indication. Its July 2026 Pharmacy Compounding Advisory Committee agenda item is an advisory section 503A bulks-list discussion, not drug approval or proof that MOTS-c treats obesity or osteoporosis.

Is MOTS-c better than SS-31 for mitochondrial health?

There is no evidence-based universal ranking. The peptides have different biology, evidence, regulatory status, populations, and endpoints. MOTS-c research is largely preclinical and biomarker-focused, while Forzinity’s labeled evidence applies to a small, specific Barth syndrome population. Neither supports a broad “best mitochondrial peptide” claim.

Can MOTS-c and SS-31 be used together?

Do not build that combination from an online protocol. There is no broad FDA-approved combination indication. A responsible review would need the diagnosis or goal, exact products, evidence limits, medicines, allergies, kidney and metabolic context, product sources, monitoring, and stop criteria.

What are red flags when buying SS-31 or MOTS-c online?

Red flags include no-prescription checkout, research-use vials promoted for people, a claim that generic “SS-31” is Forzinity, copied dosing or conversion charts, hidden pharmacy or manufacturer sourcing, “FDA approved in July” language, and guaranteed energy, weight, muscle, performance, or anti-aging outcomes.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Forzinity (elamipretide hydrochloride) current prescribing information PubMed: MOTS-c promotes metabolic homeostasis in cell and mouse research PubMed: Acute endurance exercise and circulating mitochondrial-derived peptides in humans PubMed: Elamipretide (SS-31) nomenclature and mitochondrial research ClinicalTrials.gov: Elamipretide study search FDA: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting Federal Register: FDA Pharmacy Compounding Advisory Committee July 2026 meeting notice FDA: Compounding and the FDA—Questions and Answers Peptide12: Compounded MOTS-c injection Peptide12: MOTS-c vs NAD+Peptide12: MOTS-c vs CoQ10 Peptide12: MOTS-c vs PQQ Peptide12: MOTS-c vs creatine Peptide12: FDA July 2026 peptide compounding meeting Peptide12: Peptide pharmacy quality checklist Peptide12: Peptides vs supplements Peptide12: How online peptide therapy works